# reload+after+2024-01-22 23:44:19.167600
address1§245 First Street, Riverview II
address2§18th Floor
city§Cambridge
state§MA
zip§02142
country§United States
phone§857 327 8778
fax§617 890 6595
website§https://www.cyclerion.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018, a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
fullTimeEmployees§16
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Regina  Graul Ph.D.', 'title': 'President', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Todd  Milne Ph.D.', 'title': 'Senior Vice President of External Innovation', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jessica  Rennekamp', 'title': 'Associate Director of Corporate Communications', 'exercisedValue': 0, 'unexercisedValue': 0}]
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.787
priceToSalesTrailing12Months§6.830814
currency§USD
dateShortInterest§1702598400
forwardEps§-1.31
exchange§NCM
quoteType§EQUITY
shortName§Cyclerion Therapeutics, Inc.
longName§Cyclerion Therapeutics, Inc.
firstTradeDateEpochUtc§1552915800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§dd748c39-0459-359f-9a4f-d9343a16eaf1
gmtOffSetMilliseconds§-18000000
recommendationMean§2.0
recommendationKey§buy
quickRatio§3.891
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
